MX2008011843A - Polimorfos de n-(4-cloro-3-metil-5-isoxazolil)2-[2-metil-4,5-(meti lendioxi)fenilacetil]tiofeno-3-sulfonamida, sal de sodio. - Google Patents

Polimorfos de n-(4-cloro-3-metil-5-isoxazolil)2-[2-metil-4,5-(meti lendioxi)fenilacetil]tiofeno-3-sulfonamida, sal de sodio.

Info

Publication number
MX2008011843A
MX2008011843A MX2008011843A MX2008011843A MX2008011843A MX 2008011843 A MX2008011843 A MX 2008011843A MX 2008011843 A MX2008011843 A MX 2008011843A MX 2008011843 A MX2008011843 A MX 2008011843A MX 2008011843 A MX2008011843 A MX 2008011843A
Authority
MX
Mexico
Prior art keywords
methyl
polymorphs
isoxazolyl
sulfonamide
thiophene
Prior art date
Application number
MX2008011843A
Other languages
English (en)
Spanish (es)
Inventor
John F Reichwein
Tim Hansen
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Publication of MX2008011843A publication Critical patent/MX2008011843A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2008011843A 2006-03-13 2007-03-12 Polimorfos de n-(4-cloro-3-metil-5-isoxazolil)2-[2-metil-4,5-(meti lendioxi)fenilacetil]tiofeno-3-sulfonamida, sal de sodio. MX2008011843A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78186106P 2006-03-13 2006-03-13
PCT/US2007/006277 WO2007106467A2 (en) 2006-03-13 2007-03-12 Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl)2-[2-methyl-4,5-(methylenedioxy) phenylacetyl]thiophene-3-sulfonamide, sodium salt

Publications (1)

Publication Number Publication Date
MX2008011843A true MX2008011843A (es) 2008-10-02

Family

ID=38335653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011843A MX2008011843A (es) 2006-03-13 2007-03-12 Polimorfos de n-(4-cloro-3-metil-5-isoxazolil)2-[2-metil-4,5-(meti lendioxi)fenilacetil]tiofeno-3-sulfonamida, sal de sodio.

Country Status (14)

Country Link
US (1) US20090104265A1 (enExample)
EP (1) EP1996582A2 (enExample)
JP (1) JP2009530279A (enExample)
KR (1) KR101019264B1 (enExample)
CN (1) CN101443329A (enExample)
AU (1) AU2007225206B2 (enExample)
BR (1) BRPI0709384A2 (enExample)
CA (1) CA2644134A1 (enExample)
IL (1) IL193682A0 (enExample)
MX (1) MX2008011843A (enExample)
NZ (1) NZ570943A (enExample)
RU (1) RU2412941C2 (enExample)
WO (1) WO2007106467A2 (enExample)
ZA (1) ZA200807302B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004268A1 (en) * 2007-03-13 2009-01-01 Given Bruce D Methods and Compositions for Treatment of an Interstitial Lung Disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5793705A (en) * 1996-09-18 1998-08-11 International Business Machines Corporation Ultrasonic liquid level gauge for tanks subject to movement and vibration
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4097893B2 (ja) * 2000-12-05 2008-06-11 株式会社エフ・ティ・エスコーポレーション 対向ターゲット式スパッタ方法及び導電性膜の形成方法
JP2005527523A (ja) * 2002-03-15 2005-09-15 ノバルティス　アクチエンゲゼルシャフト ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2007106467A3 (en) 2007-10-25
JP2009530279A (ja) 2009-08-27
US20090104265A1 (en) 2009-04-23
RU2412941C2 (ru) 2011-02-27
BRPI0709384A2 (pt) 2011-03-22
CN101443329A (zh) 2009-05-27
AU2007225206B2 (en) 2010-08-05
EP1996582A2 (en) 2008-12-03
CA2644134A1 (en) 2007-09-20
ZA200807302B (en) 2009-11-25
IL193682A0 (en) 2009-05-04
KR101019264B1 (ko) 2011-03-07
RU2008136316A (ru) 2010-04-20
AU2007225206A1 (en) 2007-09-20
NZ570943A (en) 2010-09-30
WO2007106467A2 (en) 2007-09-20
KR20080106926A (ko) 2008-12-09

Similar Documents

Publication Publication Date Title
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
BRPI0716880A2 (pt) Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
NO20070470L (no) Sammensetninger og fremgangsmater for behandling av dyslipidemi
ATE517099T1 (de) Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
HUP0400405A3 (en) Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
IL179758A0 (en) Substituted tetrahydro - 2h - isoquinolin - 1 - one derivatives, method for the production thereof, and use of the same as medicaments
ATE530519T1 (de) Cyclobutylaminderivate
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
IL180309A0 (en) 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nachr ligands for the treatment of cns diseases
IL183700A0 (en) Process for production of (4,5-dihydroisoxazol-3-yl)thio-carboxamidine salts
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
NZ591498A (en) Novel phenylamino isonicotinamide compounds
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
FR2869029B1 (fr) Procede de production d'une poudre d'alpha-alumine
EP2119713A4 (en) 2-METHYL-3- (3,4-METHYLENDIOXYPHENYL) PROPANAL AND METHOD OF MANUFACTURING THEREOF
IL199902A0 (en) Orotate antimetabolite derivatives, methods of producing the same and uses thereof
ZA201006211B (en) Method for the production of 3,6-dihydro-1,3,5-triazine derivatives for metformin and paraldehtde derivatives
MX2008011843A (es) Polimorfos de n-(4-cloro-3-metil-5-isoxazolil)2-[2-metil-4,5-(meti lendioxi)fenilacetil]tiofeno-3-sulfonamida, sal de sodio.
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
EP2133344A4 (en) PROCESS FOR CONTINUOUS PRODUCTION OF 2,5-DIHYDROFURANE
FR2871793B1 (fr) Procede de production d'une poudre d'alpha-alumine
WO2008019072A3 (en) Polymorphs of n-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)-amino]sulfonyl}-2-thiophene-carboxamide

Legal Events

Date Code Title Description
FA Abandonment or withdrawal